How to Build a Hair Loss Protocol: A Framework
Published by AmpleLab Research
Androgenetic alopecia is not a single-mechanism condition. It involves at least two well-established overlapping processes: elevated sensitivity to dihydrotestosterone at the follicle level and the downstream disruption of the hair growth cycle that follows. Evidence also suggests that changes in the perifollicular vascular environment may contribute to progression, though this remains an area of active research rather than settled consensus. Targeting only one of these while ignoring the others is common, and is often why single-product approaches underperform against expectations.
A protocol is an attempt to address more than one mechanism simultaneously, with each intervention assigned to a specific part of the picture. This article sets out a framework for thinking about how to construct one. It is not a treatment guide: what applies to any individual depends on the pattern and severity of their hair loss, their existing treatments, their scalp tolerance, and their personal constraints. The framework is for people who have done the research and want a way to organise what they know into something coherent and practical.
The framework has three biological targets and one delivery consideration. They are covered in order.
In androgenetic alopecia, dihydrotestosterone (DHT) binds to androgen receptors in genetically susceptible follicles and progressively shortens the anagen phase until the follicle miniaturises. This is the primary upstream driver of the condition. Addressing it at the source is the most direct intervention available.
All three options below are medicines rather than cosmetics and sit outside the scope of this article beyond this section. They are included because a complete protocol framework should acknowledge the upstream layer honestly.
A type II 5-alpha reductase inhibitor that reduces systemic DHT production by approximately 70%. The most widely prescribed and evidence-backed oral treatment for male androgenetic alopecia, with a substantial RCT evidence base. Prescription-only. Anyone considering it should do so through a prescriber who can assess suitability and discuss the known side effect profile.
A dual type I and type II 5-alpha reductase inhibitor that reduces systemic DHT by approximately 95%, making it more potent than finasteride. Clinical trials comparing the two directly have generally shown superior outcomes for dutasteride. Prescribed off-label for AGA in the UK (licensed for benign prostatic hyperplasia). Side effect profile is broadly similar to finasteride with greater DHT suppression depth.
A topical treatment proposed to act through local effects on androgen metabolism and follicular signalling, including a weak estrogenic effect at the follicle level that may extend the anagen phase. Estrogen is known to promote anagen retention, which is part of why AGA presents differently in women and why post-menopausal hair loss often accelerates as estrogen declines. The 17α configuration is specifically selected for its low systemic estrogenic activity, making this local follicular effect achievable without meaningful systemic estrogen exposure. Less potent than oral finasteride or dutasteride in terms of DHT suppression, but the localised mechanism gives it a more benign side effect profile. Licensed for AGA in some European markets, notably Germany (Ell-Cranell Alpha), but not widely available in the UK as a licensed product. The topical administration mechanism makes it conceptually compatible with a broader topical protocol.
Why this matters for the rest of the protocol
If the androgen pathway is left unaddressed, the upstream driver of follicle miniaturisation continues operating. Topical actives targeting vascular support and follicular signalling work downstream of this mechanism. They may slow or partially counteract miniaturisation, but they are not substitutes for addressing the primary cause in people with significant androgenetic alopecia. Many users include both a systemic approach and a topical protocol. The two operate on different parts of the same biology.
The vascular hypothesis of androgenetic alopecia proposes that reduced perifollicular blood supply is an active contributor to follicle miniaturisation, not simply a consequence of it. As AGA progresses, perifollicular fibrosis develops around the follicle, compressing its blood supply and degrading the environment the follicle needs to sustain a full anagen phase. Supporting vascular supply to the follicle is a mechanistically coherent target.
Two topical interventions operate primarily at this level:
2-Deoxy-D-Ribose (2dDR) is a small sugar molecule that upregulates vascular endothelial growth factor (VEGF) and promotes endothelial cell proliferation in laboratory models. VEGF is a primary mediator of perifollicular angiogenesis: the growth of blood vessels around the follicle that sustains the anagen phase. A 2024 animal study (Anjum et al.) produced hair regrowth outcomes comparable to minoxidil in that animal model across key vascular and follicular markers. For a detailed comparison, see 2dDR vs Minoxidil: What the Research Actually Shows. Apply to the scalp daily.
Minoxidil also operates primarily through vascular mechanisms: it upregulates VEGF in dermal papilla cells and is a known vasodilator. It is a medicine (prescription-only in oral form; topical versions available over the counter in many formulations) with a substantial evidence base for androgenetic alopecia. Many people who use topical cosmetic actives also use minoxidil alongside them. The mechanisms are adjacent, not identical, and the two approaches can coexist in a protocol. Some users choose topical cosmetic actives specifically for use cases where minoxidil is unsuitable, such as scalp sensitivity or microneedling protocols where glycol-containing minoxidil formulations are not preferred.
Copper peptides operate through a distinct mechanism from the vascular interventions above. Rather than targeting blood supply directly, they work through peptide-copper signalling pathways that are relevant to tissue remodelling, growth factor activity, and follicle health. The two relevant compounds are structurally similar but distinct in their research focus:
AHK-Cu (Copper Tripeptide-3) is a synthetic copper peptide analogue investigated specifically in hair follicle research contexts. A study by Pyo et al. (2007) demonstrated increased hair shaft elongation, dermal papilla cell proliferation, and upregulation of key growth factors including VEGF and IGF-1 in human hair follicle culture at 1%. For scalp and hair loss protocols, AHK-Cu is often the most directly relevant copper peptide choice. Apply to the scalp daily, or immediately after microneedling sessions.
GHK-Cu (Copper Tripeptide-1) is the naturally occurring human plasma tripeptide with a broad research profile spanning collagen synthesis, skin remodelling, wound healing, and antioxidant activity. It also has hair-adjacent evidence: GHK-Cu has been shown to upregulate VEGF and exhibits growth factor activity relevant to the perifollicular environment, though the direct hair follicle evidence is less specific than that of AHK-Cu. Users who want copper peptide coverage for both scalp and skin can use GHK-Cu alongside AHK-Cu: apply them at different times of day rather than layering two copper peptide complexes on the same area simultaneously. For example, AHK-Cu in the morning and GHK-Cu in the evening, or vice versa. For a direct comparison of the two compounds, see GHK-Cu vs AHK-Cu: Which Copper Peptide Is Right for You?
A note on concentration
The research behind both copper peptides uses concentrations at meaningful active levels. Many commercial products include copper peptides as minor components of multi-ingredient blends, without disclosing how much of the active is actually present. For a protocol to reflect what the research uses, stated concentration matters. Both AmpleLab serums are formulated at 1% (10mg/mL) of the respective copper peptide as the sole active. For more on how to evaluate concentration claims, see what most copper peptide labels don't tell you.
Topical actives face a structural barrier in the stratum corneum, which limits how much of an active reaches the dermal layer where follicle activity occurs. Copper peptides are relatively large hydrophilic molecules. Getting them past the stratum corneum at meaningful concentrations requires either a delivery system designed to enhance penetration, or temporary barrier disruption.
Microneedling creates temporary micro-channels through the stratum corneum, significantly increasing the penetration of topical actives applied immediately after. It also independently stimulates perifollicular blood flow and growth factor release, making it a dual-mechanism adjunct: it enhances delivery of the topical actives listed above while also contributing directly to the vascular target in layer 2.
The formulation of the topical active matters significantly here. Glycol-containing serums introduce a penetration risk when used through microneedle channels: glycol solvents that are well tolerated on intact skin may cause irritation at the concentrations reached dermally via micro-channels. Glycol-free formulations are commonly preferred for post-microneedling application, which is why all three AmpleLab serums use a glycol-free aqueous carrier.
The three targets and one delivery consideration above map to a practical protocol structure. The following is an example protocol using AmpleLab's product range as a case study: it is not a prescription, and the underlying framework applies to any products that address the same mechanisms.
AHK-Cu and 2dDR address different mechanisms: peptide signalling and vascular VEGF upregulation respectively. Using both is not redundant. They can be applied in the same session without conflict. Microneedling amplifies the delivery of both and adds its own independent contribution to scalp vascularity.
Hair loss protocols require patience that most people underestimate. The hair growth cycle means that even if a treatment is stimulating follicle activity from week one, visible results are only apparent once follicles that entered anagen under the influence of the treatment have grown long enough to be visible. This takes months, not weeks. For a detailed breakdown of why, see the results timeline article.
The minimum meaningful assessment window is six months of consistent use. Evaluating a protocol at six weeks is not a fair test of whether it is working. This applies to any topical intervention, regardless of the active involved.
Can I use AHK-Cu and 2dDR in the same protocol?
Yes. They operate through distinct mechanisms: AHK-Cu via peptide-copper signalling at the follicle level; 2dDR via VEGF upregulation and angiogenic activity in the perifollicular vasculature. No incompatibility between the two has been reported. They can be applied in the same session or at different times of day according to personal preference.
Can I use these alongside minoxidil?
Generally yes, though spacing applications is sensible, particularly on microneedling days. Minoxidil formulations containing propylene glycol are not recommended for post-microneedling application due to the risk of driving glycols into the skin at higher-than-normal concentrations. Minoxidil foam (alcohol-based, glycol-free) may be a more appropriate option for immediate post-microneedling use. Apply topical cosmetic serums first on microneedling days, then minoxidil separately if needed.
Do I need to microneedle for the serums to work?
No. Both AHK-Cu and 2dDR are active without microneedling. Microneedling significantly enhances topical absorption and contributes its own independent effects, but it is an adjunct rather than a prerequisite. The research behind both compounds does not require microneedling as a delivery mechanism. Many users apply the serums daily without microneedling and incorporate a microneedling session weekly or biweekly as an optional enhancement.
Should I use AHK-Cu or GHK-Cu for a hair protocol?
AHK-Cu is often the most directly relevant copper peptide for hair-focused protocols. GHK-Cu has a broader research profile across skin remodelling and wound healing, but the available in vitro hair follicle evidence is more specific to AHK-Cu. GHK-Cu is well suited to users who also want copper peptide activity for face and skin, and can be used alongside AHK-Cu on the scalp without conflict. For a full comparison, see GHK-Cu vs AHK-Cu: Which Copper Peptide Is Right for You?
How do I know if the protocol is working?
Stabilisation is often the first sign: hair loss that was progressive before the protocol slows or stops. Regrowth, if it occurs, follows later. Because the hair growth cycle means there is an inherent lag between follicle activity and visible hair, meaningful assessment requires at least six months of consistent use. See the results timeline article for a detailed explanation of what to expect and when.
The effect of tripeptide-copper complex on human hair growth in vitro
Pyo HK et al. — 2007 PubMed ↗
Stimulation of hair regrowth in an animal model of androgenic alopecia using 2-deoxy-D-ribose
Anjum MA et al. — Frontiers in Pharmacology, 2024 PubMed ↗
2-deoxy-D-ribose upregulates vascular endothelial growth factor (VEGF) and stimulates angiogenesis
Dikici S et al. — Microvascular Research, 2020 PubMed ↗
Control of hair growth and follicle size by VEGF-mediated angiogenesis
Yano K, Brown LF, Detmar M — Journal of Clinical Investigation, 2001 PubMed ↗
A randomised evaluator blinded study of effect of microneedling in androgenetic alopecia
Dhurat R et al. — International Journal of Trichology, 2013 PubMed ↗
Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells
Lachgar S et al. — British Journal of Dermatology, 1998 PubMed ↗
AmpleLab products are cosmetic formulations registered on the UK Cosmetic Products Notification Portal. They are not medicines and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any treatment for hair loss.
AmpleLab.